Hemolytic uremic syndrome associated with clopidogrel: A case report

Archives of Internal Medicine

Volumn 160, Issue 9, 2000, Pages 1370-1372

  Moy, Beverly ^a   Wang, John C ^a   Raffel, Glen D ^b   Marcoux II, J Paul ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; METOPROLOL; RANITIDINE; TERAZOSIN; TICLOPIDINE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; CORONARY STENT; DISEASE COURSE; DRUG SAFETY; DRUG STRUCTURE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; MALE; NEUTROPENIA; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS;

EID: 0034621365     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.9.1370     Document Type: Article

References (18)

1. Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation. 1996;94: 1519-1527.
2. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-1688.
3. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulation therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-1089.
4. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet. 1991;337:774-776.
5. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevenfion of stroke in high risk patients. N Engl J Med. 1989;321: 501-507.
6. Ellie E, Durrieu C, Besse P, Julien J, Gbipki-Benissan G. Thrombotic thrombocytopenic purpura associated with ticlopidine. Stroke. 1992; 23:922-923.
7. Kovacs MJ, Soong PY, Chin-Yee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother. 1993;27:1060-1061.
8. Ariyoshi K, Shinohara K, Ruirong X. Thrombotic thrombocytopenic purpura caused by ticlopidine successfully treated by plasmapheresis [letter]. Am J Hematol. 1997;54:175-176.
9. Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura [letter]. N Engl J Med. 1997;337:1245.
10. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med. 1998; 128:541-544.
11. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129:394-405.
12. CAPRIE Steering Committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
13. Gordon LI, Kwaan HC. Cancer-and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 1997;34:140-147.
14. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation. 1997;95: 809-813.
15. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med. 1984;100:535-540.
16. Antman K, Skarin A, Mayer R. Microangiopathic hemolytic anemia and cancer: a review. Medicine. 1979;58:388-384.
17. Lohrman HP, Adam W, Heymer B, Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma: report of eight cases. Ann Intern Med. 1973;79:368-375.
18. Holmes DR Jr, Hirshfeld J Jr, Faxon D, Vlietstra RE, Jacobs A, King SB III. ACC expert consensus document on coronary artery stents: document of the American College of Cardiology. J Am Coll Cardiol. 1998;32:1471-1482.